Digoxin and Heart Failure: Are We Clear Yet?
The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5–0.9 ng/mL) has been shown to decrease mortality in heart failure patients. Multiple trials in different patient populations also show b...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript
2017-05-01
|
| Series: | Cardiovascular Innovations and Applications |
| Subjects: | |
| Online Access: | http://www.ingentaconnect.com/content/cscript/cvia/2017/00000002/00000003/art00003 |